Logo
x

Search category

Subscribe Now

Sumitomo Pharma

Sumitomo Pharma and Otsuka Failed to Meet its Primary Endpoints of Ulotaront in P-III Trials (DIAMOND 1 & 2) for Schizophrenia

Sumitomo Pharma and Otsuka Failed to Meet its Primary Endpoints of Ulotaront in P-III Trials (DIAMOND 1 & 2) for Schizophrenia

  • August 1, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.